

Mike Becker



Country: Switzerland

Contact e-mail: becker.mo@gmail.com

Year of birth: 1976

Mains diplomas:

MD: 2006 (Marburg, Germany)

Rheumatologist: 2015 (Germany)

MSc (Immunology): 2006 (Oxford, UK)

Current position and hospital/university:

Attending physician, Dept of Rheumatology, University Hospital Zürich, Switzerland

Previously: Rheumatology in training, Dept. of Rheumatology and Clinical Immunology, Charité University Hospital Berlin, Germany

Position within EULAR/international experience:

Member of the EULAR task force "Treatment recommendations for Systemic Sclerosis"

Role as EMEUNET working group member:

Member of the Newsletter subgroup

Areas of Research/Interest:

Systemic sclerosis, epidemiology, basic research, patient reported outcomes, vasculitis, basic immunology

Keywords:

outcomes research, epidemiology, systemic sclerosis, vasculitis, immunology

Publications:

- Cutolo M, Herrick AL, Distler O, **Becker MO**, Beltran E, Carpentier P, Ferri C, Inanç M, Vlachoyiannopoulos P, Chadha-Boreham H, Cottreel E, Pfister T, Rosenberg D, Torres JV, Smith V; CAP Study Investigators. Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study. *Arthritis Rheumatol.* 2016 Oct;68(10):2527-39.

- **Becker MO**, Riemekasten G. Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course. *Expert Rev Clin Immunol*. 2016 Feb;12(2):115-35.
- **Becker MO**, Kill A, Kutsche M, Guenther J, Rose A, Tabeling C, Witzernath M, Kühl AA, Heidecke H, Ghofrani HA, Tiede H, Schermuly RT, Nickel N, Hoepfer MM, Lukitsch I, Gollasch M, Kuebler WM, Bock S, Burmester GR, Dragun D, Riemekasten G. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. *Am J Respir Crit Care Med*. 2014 Oct 1;190(7):808-17.
- **Becker MO**, Schohe A, Weinert K, Huscher D, Schneider U, Burmester GR, Riemekasten G. Responders to cyclophosphamide: results of a single-centre analysis among systemic sclerosis patients. *Ann Rheum Dis*. 2012 Dec;71(12):2061-2.
- Riemekasten G, Philippe A, Näther M, Slowinski T, Müller DN, Heidecke H, Matucci-Cerinic M, Czirják L, Lukitsch I, **Becker M**, Kill A, van Laar JM, Catar R, Luft FC, Burmester GR, Hegner B, Dragun D. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. *Ann Rheum Dis*. 2011 Mar;70(3):530-6.
- **Becker MO**, Brückner C, Scherer HU, Wassermann N, Humrich JY, Hanitsch LG, Schneider U, Kawald A, Hanke K, Burmester GR, Riemekasten G. The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study. *Ann Rheum Dis*. 2011 Jul;70(7):1340-1.
- **Becker M**, Cotena A, Gordon S, Platt N. Expression of the class A macrophage scavenger receptor on specific subpopulations of murine dendritic cells limits their endotoxin response. *Eur J Immunol*. 2006 Apr;36(4):950-60.

Date of last update of the CV:

Dezember 2016